# US Anthrax Vaccine Market

> US Anthrax Vaccine Market Research Report Information By Vaccine Type (Cell Free PA Vaccine, Anthrax Vaccine Adsorbed (AVA), Anthrax Vaccine Precipitated (AVP), and Live Attenuated Vaccine), By Applications (Animal Use and Human Use), and By Distribution Channel (Hospitals, Pharmacies, and Other Distribution Channels)—United States Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.26%
- **2024:** $ 216 Million
- **2025:** $ 230.4 Million
- **2035:** $ 421.2 Million
- **Key Players:** Emergent BioSolutions (US), GlaxoSmithKline (GB), Sanofi Pasteur (FR), Pfizer (US), Baxter International (US), Hoffmann-La Roche (CH), Novartis (CH), Merck & Co. (US)

**Report ID:** MRFR/Pharma/20408-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-anthrax-vaccine-market-22008

---

## Market Summary

## **US Anthrax Vaccine Market Overview**

The US Anthrax Vaccine Market Size was valued at USD 5.9 billion in 2023. The industry is projected to grow from USD 6.1 billion in 2024 to USD 8.7 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.00% during the forecast period (2024 - 2032). An increase in government contracts and funding and rising demand for biodefense preparedness are the primary market drivers propelling the market's expansion.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **US Anthrax Vaccine Market Trends**

### **Increasing advancements in vaccine technology are driving the market growth**

The creation of anthrax vaccines with improved safety profiles is made possible by cutting down on the possibility of side effects and boosting public trust in vaccination programs, which is driving the market CAGR. Examples of these advanced vaccine technologies include protein subunit vaccines and recombinant DNA approaches. By focusing on certain anthrax bacteria components, next-generation vaccine platforms allow the development of anthrax vaccinations with increased efficacy, improving infection prevention and minimizing the need for booster doses.

By boosting vaccine efficiency and cost-effectiveness and maybe lowering the number of doses needed for protection, novel adjuvants can strengthen the immune response to anthrax vaccinations, improving their efficacy and potentially propelling market development.

Additionally, early detection of anthrax outbreaks by surveillance systems enables quick action by the public health community. The discovery of anthrax cases may lead to vaccination drives and stockpiling initiatives, which in turn may increase demand for the vaccine. The utilization of surveillance data yields significant insights into evaluating the potential for anthrax exposure across various geographic areas or demographic groups. The industry is growing because enhanced readiness initiatives, such as immunization campaigns and procurement agreements, are frequently directed by surveillance results.

Public health organizations use surveillance systems to guide their response plans for anthrax outbreaks, which include resource allocation and vaccination preparations. Investment in anthrax vaccines and associated infrastructure is driven by the requirement for readiness, which propels market expansion.

Furthermore, animals affected with anthrax illness, which affects cattle and other ruminants, die. The soil-borne spore-forming bacterium Bacillus anthracis is the cause of this zoonotic illness, which affects both people and animals in the United States. Because of growing efforts by industry participants to create [animal vaccines](../../../reports/animal-vaccines-market-7184) and growing awareness among animal owners about anthrax vaccination, the animal-use anthrax vaccine sector is anticipated to hold a sizable market share throughout the projected period. Thus, this drives the US Anthrax Vaccine market revenue.

## **US Anthrax Vaccine Market Segment Insights**

### **US Anthrax Vaccine Vaccine Type Insights**

Based on Vaccine Type, the US Anthrax Vaccine market segmentation includes cell-free PA vaccine, anthrax vaccine adsorbed (AVA), anthrax vaccine precipitated (AVP), and live attenuated vaccine. In 2023, the cell-free PA vaccine segment dominated the market. The goal of the cell-free PA vaccine is to increase the body's ability to produce antibodies against the protective antigen (PA) found in the anthrax toxin. In order for the anthrax bacteria to infect cells and spread illness, PA is required. The vaccination seeks to prevent anthrax infection by neutralizing the toxin via targeting PA.

Cell-free protein synthesis methods are used in the production of the Cell-Free PA Vaccine, in contrast to conventional anthrax vaccines that are made with live or attenuated bacteria. This novel manufacturing technique has a number of benefits, including scalability, less danger of contamination, and exact control over protein output.

The anthrax vaccine Adsorbed (AVA) category is anticipated to be the fastest growing. AVA is regularly administered to US military faculty as a component of the Department of Defense's (DoD) Bacillus anthracis Immunization Vaccination Program (AVIP). Military personnel deployed to The vaccination is necessary to guard against possible anthrax exposure in high-risk locations or when allocated to particular occupational duties.

### **US Anthrax Vaccine Applications Insights**

Based on Applications, the US Anthrax Vaccine market segmentation includes animal use and human use. The category with the highest income generation in 2023 was animal use. To prevent anthrax outbreaks on farms and ranches, livestock, including cattle, sheep, and goats, are vaccinated against the disease in the United States. Vaccinating cattle is essential for maintaining animal health and avoiding financial losses brought on by anthrax-related fatalities and disease outbreaks.

In high-risk locations or places with a history of anthrax outbreaks, government organizations, such as the US Department of Agriculture (USDA) and state veterinary authorities, may conduct anthrax vaccination programs for cattle. The goals of these initiatives are to reduce the impact on agricultural output and manage the spread of anthrax.

The US Anthrax Vaccine human use portion market is expected to grow quickly during the forecast time frame. AVA can be used for post-exposure prophylaxis (PEP) to prevent anthrax infection in anyone who may have been exposed to the bacteria in the case of a confirmed or suspected anthrax exposure. It is advised to combine PEP with AVA, antibiotics, and other medical treatments.

**Figure 1: US Anthrax Vaccine Market, by Applications, 2023 & 2032 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **US Anthrax Vaccine Distribution Channel Insights**

Based on the Distribution Channel, the US Anthrax Vaccine market segmentation includes hospitals, pharmacies, and other distribution channels. The hospitals category leads the market. Vaccination standards and public health recommendations permit hospitals with immunization clinics or occupational health departments to provide AVA to emergency responders, medical staff, and other high-risk persons. Hospitals have the option to engage in community outreach programs aimed at increasing public knowledge of the anthrax vaccine, endorsing vaccination drives, and furnishing them with details on vaccine accessibility, qualifying requirements, and administration periods.

The US Anthrax Vaccine market’s pharmacies segment is anticipated to grow fastest during the projection period. The distribution and administration of vaccines, such as AVA, during anthrax epidemics or bioterrorism occurrences are among the public health emergency preparation initiatives in which pharmacies may take part. Under some circumstances, pharmacists could be permitted to provide AVA to people who have been classified as high-risk or who qualify for immunization.

### **US Anthrax Vaccine Country Insights**

The US is a hub for vaccine innovative work, with government organizations, drug partnerships, and academic institutions effectively attempting to propel Bacillus anthracis vaccine innovation. Cutting-edge Bacillus anthracis vaccine improvement is filled by interests in research, clinical preliminaries, and item development, all of which support market extension. The US government places a high priority on being ready for biodefense. This may result in a build-up of anthrax vaccine supplies and the possibility of tailored immunization campaigns for high-risk populations. The United States makes significant investments in biodefense R&D.

This may result in the development of anthrax vaccinations that are more effective, simpler to administer, or combine protection against many hazards.

## **US Anthrax Vaccine Key Market Players & Competitive Insights**

The industry's leading players will keep investing heavily in R&D to expand their product lines, which will propel the US Anthrax Vaccine market's growth. Contractual agreements, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the US Anthrax Vaccine industry must offer reasonably priced products and services.

One of the main strategies manufacturers use in the worldwide US Anthrax Vaccine market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. Some of the biggest medical benefits in recent years have come from the US Anthrax Vaccine sector. Major players in the US Anthrax Vaccine market, including Merck & Co., Inc., Emergent Bio-Solutions, Zoetis, Inc., PharmAthene, Inc., Biogenesis Bago S.A, Porton Biopharma Limited, Colorado Serum, Merial, Inc., Tiankang, Agrovet, Bayer AG, and others, are attempting to increase market demand by investing in research and development operations.

A biopharmaceutical company, Merck and Co. Inc. is committed to the research, development, manufacture, and marketing of biologic therapies, pharmaceuticals recommended by doctors, vaccines, and products for the health of animals. It provides prescription products for the treatment of conditions related to cancer, diabetes, heart disease, respiratory, infectious, immune, and other conditions. The company offers products for animal health, including hydroponics, chicken, antibodies, and animals. Merck supplies managed medical care providers, veterinarians, businesses, and animal producers with pharmaceuticals and animal welfare products.

A life sciences business called Emergent BioSolutions Inc. offers specialized solutions to meet medical requirements and public health threats (PHTs). Chemical, biological, radiological, travel health, emerging health crises, nuclear and explosives (CBRNE), emerging infectious illnesses, and acute/emergency care are among the PHTs that its solutions assist in addressing. It provides contract development and manufacturing services in addition to vaccines, medicines, and drug-device combo products. The pipeline prospects of Emergent are intended to treat influenza and dengue fever. Additionally, it provides government agencies and private clients with specific products.

### **Key companies in the US Anthrax Vaccine market include**

- [Merck & Co., Inc.](https://www.msd-animal-health.co.za/products/anthravax/)
- Emergent Bio-Solutions
- Zoetis, Inc.
- PharmAthene, Inc
- Biogenesis Bago S.A
- Porton Biopharma Limited
- Colorado Serum
- Merial, Inc.
- Tiankang
- Agrovet
- Bayer AG

## **US Anthrax Vaccine Industry Developments**

**October 2022:** The US Biomedical Advanced Research and Development Authority (BARDA), a division of the Department of Health and Human Services (HHS)'s Administration for Strategic Preparedness and Response (ASPR), has chosen ICON plc to carry out a clinical study for the anthrax vaccine AV7909. The vaccine is presently being evaluated in clinical trials.

**June 2022:** Emanant BioSolutions Inc. was granted review acceptance of the Biologics Permit Application (BLA) for AV7909 (Bacillus anthracis Immunization Adsorbed, Adjuvanted) from the US FDA. AV7909 is assessed for post-exposure prophylaxis of illness following thought or exposure openness to Bacillus anthracis in adults (age bunch 18 - 65). The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in April 2023.

## **US Anthrax Vaccine Market Segmentation**

### **US Anthrax Vaccine Vaccine Type Outlook**

- Cell-Free PA Vaccine
- Anthrax Vaccine Adsorbed (AVA)
- Anthrax Vaccine Precipitated (AVP)
- Live Attenuated Vaccine

### **US Anthrax Vaccine Applications Outlook**

- Animal Use
- Human Use

### **US Anthrax Vaccine Distribution Channel Outlook**

- Hospitals
- Pharmacies
- Other Distribution Channels

## Market Drivers

### Increased Government Funding

The US [Anthrax Vaccine](https://www.marketresearchfuture.com/reports/anthrax-vaccine-market-65902) Market is experiencing a surge in government funding aimed at enhancing national security and public health preparedness. The Department of Defense and the Department of Health and Human Services have allocated substantial budgets for the procurement and development of anthrax vaccines. In 2025, the federal budget for biodefense initiatives reached approximately 1.5 billion USD, with a significant portion directed towards anthrax vaccine research and production. This financial commitment underscores the government's recognition of the potential threat posed by anthrax as a bioterrorism agent. Consequently, increased funding is likely to stimulate innovation and production capacity within the US Anthrax Vaccine Market, fostering a more robust response to potential biological threats.

### Rising Bioterrorism Threat Perception

The perception of bioterrorism threats has escalated in recent years, significantly impacting the US Anthrax Vaccine Market. High-profile incidents and intelligence reports have heightened awareness of the potential use of anthrax as a biological weapon. This growing concern has prompted both public and private sectors to prioritize the development and stockpiling of anthrax vaccines. According to the Centers for Disease Control and Prevention, the likelihood of anthrax being used in a bioterrorism attack remains a critical issue. As a result, the demand for effective vaccines is expected to rise, driving growth in the US Anthrax Vaccine Market as stakeholders seek to mitigate risks associated with bioterrorism.

### Public Health Preparedness Initiatives

Public health preparedness initiatives are increasingly influencing the US Anthrax Vaccine Market. The federal and state governments are implementing comprehensive strategies to enhance readiness for biological threats, including anthrax outbreaks. Programs aimed at improving surveillance, response capabilities, and vaccination campaigns are being prioritized. The National Strategy for Countering Biological Threats emphasizes the importance of maintaining a robust vaccine stockpile and ensuring rapid distribution during emergencies. This proactive approach is expected to drive demand for anthrax vaccines, as public health agencies seek to protect populations from potential outbreaks. Consequently, the US Anthrax Vaccine Market is likely to benefit from these initiatives, fostering collaboration between government entities and vaccine manufacturers.

### Growing Awareness of Occupational Hazards

There is a growing awareness of occupational hazards associated with anthrax exposure, particularly among professionals in high-risk fields such as [veterinary medicine](https://www.marketresearchfuture.com/reports/veterinary-medicine-market-844), agriculture, and laboratory research. This heightened awareness is influencing the US Anthrax Vaccine Market as organizations and employers recognize the importance of vaccination for their employees. Regulatory bodies, including the Occupational Safety and Health Administration, are advocating for vaccination programs to mitigate risks in these sectors. As more companies implement mandatory vaccination policies, the demand for anthrax vaccines is expected to increase. This trend not only enhances workplace safety but also contributes to the overall growth of the US Anthrax Vaccine Market.

### Technological Innovations in Vaccine Development

Technological advancements in vaccine development are playing a pivotal role in shaping the US Anthrax Vaccine Market. Innovations such as recombinant DNA technology and novel adjuvants are enhancing the efficacy and safety profiles of anthrax vaccines. For instance, the recent introduction of next-generation vaccines has shown promise in eliciting stronger immune responses with fewer doses. The US Food and Drug Administration has been actively involved in facilitating the approval of these innovative products, which could lead to a more competitive market landscape. As these technologies continue to evolve, they are likely to attract investment and research efforts, further propelling the growth of the US Anthrax Vaccine Market.

## Future Outlook

The US Anthrax Vaccine Market is projected to grow at a 6.26% CAGR from 2025 to 2035, driven by increased bioterrorism concerns, advancements in vaccine technology, and government initiatives.

**New opportunities:**

- Development of mobile vaccination units for rapid response Partnerships with biotech firms for innovative vaccine formulations Expansion into veterinary applications to diversify revenue streams

By 2035, the market is expected to be robust, driven by strategic innovations and heightened demand.

## Segment Insights

### By Application: Prevention (Largest) vs. Post-Exposure Prophylaxis (Fastest-Growing)

In the US Anthrax Vaccine Market, the application segment is primarily driven by the need for vaccination aimed at prevention, which holds a significant share due to its critical role in bioterrorism defense and public health. Prevention strategies focus on immunizing at-risk populations to safeguard against potential anthrax outbreaks, contributing to their dominant market positioning. In contrast, post-exposure prophylaxis is experiencing rapid growth as awareness of anthrax threats increases, leading to higher government and military investment in rapid-response vaccination initiatives.

Prevention (Dominant) vs. Research and Development (Emerging)

Within the Anthrax Vaccine application segment, prevention is established as the dominant force, fostering a wide-ranging infrastructure for immunization. This proactive approach is complemented by extensive educational campaigns on the importance of anthrax vaccinations, ensuring vast coverage among high-risk groups. Meanwhile, research and development (R&D) emerges as a burgeoning segment, focusing on innovations to improve vaccine efficacy and broaden the spectrum of protective solutions. R&D efforts are being propelled by advances in biotechnology, which aim to enhance immune responses and develop more versatile antigens, ultimately aiming to provide robust protection against anthrax exposure.

### By End Use: Government Agencies (Largest) vs. Military (Fastest-Growing)

In the US Anthrax Vaccine Market, government agencies hold the largest share of the end-use segment. This dominance is primarily attributed to federal and state initiatives aimed at protecting public health through vaccination against bioterrorism and biosecurity threats. They have established numerous programs and funding to ensure the availability of anthrax vaccines, which allows them to maintain a significant presence in the market. Meanwhile, the military segment is also considerably important, as the armed forces prioritize vaccinations to safeguard personnel deployed in high-risk areas, contributing to its growth.

Government Agencies: Dominant vs. Military: Emerging

Government agencies play a crucial role in the US Anthrax Vaccine Market due to their extensive programs focused on public health and national security. They not only procure vaccines but also influence policies that encourage vaccination among at-risk populations. On the other hand, the military represents an emerging yet rapidly growing segment, driven by the increasing recognition of bioweapons threats. The military's proactive approach to vaccination and readiness enhancements showcases their commitment to safeguarding personnel, and as global tensions rise, this segment is anticipated to expand steadily. Together, these segments demonstrate the significance of preparedness against anthrax outbreaks.

### By Distribution Channel: Direct Sales (Largest) vs. Online Sales (Fastest-Growing)

In the US Anthrax Vaccine Market, the distribution of market share among various channels shows that Direct Sales holds the largest segment. This channel benefits from strong relationships with healthcare providers and government agencies, enabling consistent sales. Meanwhile, Online Sales is rapidly gaining traction as telemedicine and e-commerce become more prevalent, allowing for greater access to vaccines for end-users and health institutions alike. Moreover, Pharmacies and Hospitals also play significant roles, offering patients easy access to vaccination, but they contribute less overall to the market share compared to Direct and Online Sales.

Growth trends indicate a shift in consumer preferences toward more digital and accessible routes for purchasing vaccines. Online Sales, in particular, is expected to see an increase as more people turn to online platforms for their healthcare needs. This growth is fueled by initiatives to enhance public awareness about vaccines, especially in the wake of growing health concerns. Pharmacies are also adapting by expanding their offerings and improving stock levels, which positions them as vital players in vaccine distribution alongside hospitals, which continue to play a critical role in administering these vaccines to patients.

Direct Sales (Dominant) vs. Online Sales (Emerging)

Direct Sales is characterized by strong, established relationships with healthcare providers and governmental entities, making it the dominant channel for anthrax vaccine distribution in the U.S. It enables direct interaction between manufacturers and stakeholders, ensuring higher reliability and confidence in supply chain logistics. In contrast, Online Sales is emerging rapidly, attracting a diverse customer base with its convenience and accessibility. The rising trend of telehealth is facilitating this growth, as it allows healthcare providers to recommend vaccines online. While Direct Sales focuses on maintaining existing partnerships, Online Sales is redefining vaccination access and is likely to capture a larger share of the market as more individuals choose digital platforms for their healthcare needs.

### By Formulation Type: Liquid (Largest) vs. Lyophilized (Fastest-Growing)

In the US Anthrax Vaccine Market, the formulation type segment is characterized by a diverse range of products, with liquid formulations being the most prevalent. Liquid vaccines are favored due to their ease of administration and stability, capturing a significant share of the market. In contrast, lyophilized formulations, while currently smaller in share, are gaining traction among manufacturers and healthcare providers for their longer shelf life and stability under varying environmental conditions. Meanwhile, suspension formulations occupy a niche segment, primarily utilized in specific applications where high viscosity is required.

Formulation Type: Liquid (Dominant) vs. Lyophilized (Emerging)

Liquid anthrax vaccines are dominant in the market, offering advantages such as ease of administration and immediate efficacy, which makes them highly preferred in both clinical and emergency settings. On the other hand, lyophilized vaccines are emerging as a significant alternative due to advancements in freeze-drying technologies that enhance stability and allow for extended shelf life without refrigeration. This makes lyophilized formulations particularly appealing for stockpiling and use in potential outbreak scenarios. As interest rises in preparedness against bioterrorism, both formulations are positioned to meet unique healthcare needs in diverse scenarios.

### By Target Population: Adults (Largest) vs. High-Risk Individuals (Fastest-Growing)

In the US Anthrax Vaccine Market, the target population segment is predominantly composed of adults, who represent the largest share due to widespread vaccination campaigns aimed at this demographic. Adults generally have higher exposure risks and therefore, the uptake of the anthrax vaccine is significantly higher. Additionally, children hold a smaller but essential share in the market, especially concerning preventative measures promoted by health authorities for young populations in specific high-risk areas. The growth trends in this segment are heavily influenced by increasing awareness and education about anthrax exposure, particularly among high-risk individuals. This population segment, including healthcare workers and military personnel, is emerging as the fastest-growing due to heightened concerns around bioterrorism and zoonotic diseases. Such trends drive manufacturers to innovate and cater to the specific needs of this evolving market segment.

Adults (Dominant) vs. High-Risk Individuals (Emerging)

In the context of the US Anthrax Vaccine Market, adults remain the dominant segment due to their substantial presence in vaccination programs, reflecting a higher demand for protection against anthrax. Their established healthcare access and understanding of vaccine importance support sustained market demand. In contrast, high-risk individuals are an emerging segment, characterized by increased vaccination initiatives tailored to address specific exposure scenarios. This group includes those in occupations with heightened risk, such as military personnel and first responders, which makes them pivotal in market growth. As focus on biowarfare threats intensifies, high-risk populations are increasingly recognized for their unique needs, warranting targeted strategies from vaccine manufacturers.

## Regional Market Share Analysis

### North America : Leading Market for Vaccines

The North American region, particularly the United States, is the largest market for anthrax vaccines, holding approximately 70% of the global market share. Key growth drivers include heightened bioterrorism concerns, government initiatives for public health preparedness, and increasing investments in vaccine research and development. Regulatory support from agencies like the FDA further catalyzes market growth, ensuring safety and efficacy standards are met. The competitive landscape is robust, with major players such as Emergent BioSolutions, Pfizer, and Merck & Co. leading the charge. The presence of these companies fosters innovation and enhances market dynamics. Additionally, the U.S. government’s procurement strategies and funding for vaccine development create a favorable environment for these key players, ensuring a steady supply of anthrax vaccines to meet public health needs.

### Europe : Emerging Market Potential

Europe is witnessing a growing demand for anthrax vaccines, driven by increasing awareness of bioterrorism threats and the need for enhanced public health measures. The region holds approximately 20% of the global market share, with countries like the United Kingdom and Germany leading in vaccine research and development. Regulatory frameworks, such as the European Medicines Agency's guidelines, are pivotal in shaping the market landscape, ensuring compliance and safety in vaccine distribution. The competitive environment features key players like GlaxoSmithKline and Sanofi Pasteur, who are actively involved in developing innovative vaccine solutions. The collaboration between public health organizations and private companies is fostering advancements in vaccine technology. Furthermore, the European Union's initiatives to bolster vaccine preparedness against biological threats are expected to further stimulate market growth in the coming years.

### Asia-Pacific : Emerging Powerhouse in Vaccines

The Asia-Pacific region is emerging as a significant player in the anthrax vaccine market, driven by increasing investments in healthcare infrastructure and rising awareness of bioterrorism threats. Countries like India and Australia are at the forefront, collectively holding about 8% of the global market share. Regulatory bodies in these nations are enhancing their frameworks to support vaccine development, which is crucial for addressing public health challenges effectively. The competitive landscape is evolving, with local manufacturers and international players like AstraZeneca and Novartis expanding their presence. Collaborative efforts between governments and private sectors are fostering innovation in vaccine technology. Additionally, the region's growing focus on pandemic preparedness is likely to drive further demand for anthrax vaccines, ensuring a proactive approach to public health safety.

### Middle East and Africa : Developing Market Landscape

The Middle East and Africa region presents a developing landscape for the anthrax vaccine market, characterized by varying levels of healthcare infrastructure and regulatory frameworks. This region holds approximately 2% of the global market share, with countries like South Africa and the UAE showing potential for growth. Increasing awareness of bioterrorism and infectious diseases is driving demand for vaccines, although challenges such as funding and access to healthcare remain prevalent. The competitive environment is less saturated compared to other regions, but there is a growing interest from international players looking to enter the market. Local manufacturers are also beginning to emerge, supported by government initiatives aimed at improving public health. Collaborative efforts between international organizations and local governments are essential for enhancing vaccine accessibility and addressing public health needs effectively.

## Competitive Benchmarking

The Anthrax Vaccine Market is characterized by a competitive landscape that is shaped by a combination of innovation, strategic partnerships, and regulatory dynamics. Key players such as Emergent BioSolutions (US), GlaxoSmithKline (GB), and Merck & Co. (US) are actively engaged in enhancing their market positions through various strategic initiatives. Emergent BioSolutions (US) has focused on expanding its production capabilities to meet increasing demand, while GlaxoSmithKline (GB) emphasizes research and development to innovate its vaccine offerings. Merck & Co. (US) appears to be leveraging its extensive distribution network to enhance accessibility, thereby influencing the competitive dynamics of the market.
The market structure is moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is particularly relevant in the context of vaccine distribution. The collective influence of these major players contributes to a competitive environment where innovation and operational efficiency are paramount.
In December 2025, Emergent BioSolutions (US) announced a strategic partnership with a leading biotechnology firm to enhance its vaccine development capabilities. This collaboration is expected to accelerate the research and production of next-generation anthrax vaccines, thereby positioning Emergent as a frontrunner in the market. The strategic importance of this partnership lies in its potential to leverage advanced technologies and expertise, which could lead to more effective vaccine solutions.
In November 2025, GlaxoSmithKline (GB) launched a new initiative aimed at increasing vaccine accessibility in underserved regions. This initiative includes a commitment to provide vaccines at reduced costs to healthcare providers in low-income areas. The strategic significance of this move is twofold: it not only enhances GlaxoSmithKline's corporate social responsibility profile but also expands its market reach, potentially increasing its share in the anthrax vaccine segment.
In October 2025, Merck & Co. (US) unveiled a digital platform designed to streamline vaccine distribution and tracking. This platform utilizes advanced analytics to optimize supply chain logistics, ensuring timely delivery of vaccines to healthcare facilities. The strategic importance of this digital transformation is evident, as it positions Merck to respond more effectively to market demands and enhances its operational efficiency.
As of January 2026, current trends in the Anthrax Vaccine Market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in vaccine development and distribution. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and collaboration among key players. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This shift underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge.

## Recent News & Developments

**October 2022:** The US Biomedical Advanced Research and Development Authority (BARDA), a division of the Department of Health and Human Services (HHS)'s Administration for Strategic Preparedness and Response (ASPR), has chosen ICON plc to carry out a clinical study for the anthrax vaccine AV7909. The vaccine is presently being evaluated in clinical trials.

**June 2022:** Emanant BioSolutions Inc. was granted review acceptance of the Biologics Permit Application (BLA) for AV7909 (Bacillus anthracis Immunization Adsorbed, Adjuvanted) from the US FDA. AV7909 is assessed for post-exposure prophylaxis of illness following thought or exposure openness to Bacillus anthracis in adults (age bunch 18 - 65). The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in April 2023.

## Report Scope

| MARKET SIZE 2024 | 216.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 230.4(USD Million) |
| MARKET SIZE 2035 | 421.2(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.26% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Emergent BioSolutions (US), GlaxoSmithKline (GB), Sanofi Pasteur (FR), Pfizer (US), Baxter International (US), Hoffmann-La Roche (CH), Novartis (CH), Merck & Co. (US) |
| Segments Covered | Application, End Use, Distribution Channel, Formulation Type, Target Population |
| Key Market Opportunities | Advancements in vaccine delivery systems enhance accessibility in the US Anthrax Vaccine Market. |
| Key Market Dynamics | Regulatory scrutiny intensifies, driving innovation and competition in the US Anthrax Vaccine Market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US Anthrax Vaccine Market?**
A: The US Anthrax Vaccine Market was valued at 216.0 USD Million in 2024.

**Q: What is the projected market size for the US Anthrax Vaccine Market by 2035?**
A: The market is projected to reach 421.2 USD Million by 2035.

**Q: What is the expected CAGR for the US Anthrax Vaccine Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 6.26%.

**Q: Which companies are the key players in the US Anthrax Vaccine Market?**
A: Key players include Emergent BioSolutions, GlaxoSmithKline, Sanofi Pasteur, Pfizer, Baxter International, Hoffmann-La Roche, Novartis, and Merck & Co.

**Q: What are the main applications of anthrax vaccines in the market?**
A: The main applications include Prevention, Post-Exposure Prophylaxis, and Research and Development.

**Q: How much revenue is generated from the Prevention segment of the market?**
A: The Prevention segment generated revenues between 108.0 and 210.0 USD Million.

**Q: What is the revenue range for the Military end-use segment?**
A: The Military end-use segment is expected to generate revenues between 70.0 and 140.0 USD Million.

**Q: What distribution channels are utilized in the US Anthrax Vaccine Market?**
A: Distribution channels include Direct Sales, Online Sales, Pharmacies, and Hospitals.

**Q: What are the different formulation types available in the market?**
A: Formulation types include Liquid, Lyophilized, and Suspension.

**Q: Which target populations are prioritized in the US Anthrax Vaccine Market?**
A: Target populations include Adults, Children, and High-Risk Individuals.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-anthrax-vaccine-market-22008*